Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
about
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesCyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancerRespective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinomaRisk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data.A signature-based method for indexing cell cycle phase distribution from microarray profiles.Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer.Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues.Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Chromatin CKAP2, a new proliferation marker, as independent prognostic indicator in breast cancerHigh lymphatic vessel density and presence of lymphovascular invasion both predict poor prognosis in breast cancer.YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes.Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasiaDynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.Determinants of outcome of solitary fibrous tumors of the pleura: an observational cohort study.Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis.Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancerExpression of multidrug resistance proteins in invasive ductal carcinoma of the breastShould Histologic Grade Be Incorporated into the TNM Classification System for Small (T1, T2) Node-Negative Breast Adenocarcinomas?Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling.Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma.A study to investigate the role of p27 and cyclin E immunoexpression as a prognostic factor in early breast carcinoma.The impact of matrix metalloproteinase 2 on prognosis and clinicopathology of breast cancer patients: a systematic meta-analysis.Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.Promoter Methylation Status Modulate the Expression of Tumor Suppressor (RbL2/p130) Gene in Breast CancerDifferences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma.Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewComparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group StudyHigh Expression of Three-Gene Signature Improves Prediction of Relapse-Free Survival in Estrogen Receptor-Positive and Node-Positive Breast Tumors.Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancerQuantum dots-based double imaging combined with organic dye imaging to establish an automatic computerized method for cancer Ki67 measurementKi-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slidesInterobserver Variability of Ki-67 Measurement in Breast Cancer.The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.
P2860
Q26743510-86C34ABE-ABF2-4159-A09E-6D7E65D28B62Q28277288-0085D9A5-8C68-42DB-870D-58E7DFC25C09Q28730529-3D1550FF-612A-4524-9DA2-D7539C646314Q30854643-B64D056C-3EB8-4F49-94FC-712459C42B37Q33368855-180B980E-AF36-4D90-9057-1E043B994904Q33424041-12CE45DC-6D4C-4708-A8E2-5385AC4E250CQ33484404-5733B12A-49A6-43D6-854E-3704F1A1916DQ33501853-7E0A53B1-7940-4F4D-93A2-98F3028B721BQ33533301-0DA90EFE-5179-4454-9069-38DC3E21A5E4Q33698446-22668971-E668-428B-A9F5-A9613E4D5AD4Q33699104-7F3786F9-271B-40A1-A340-5225720146ABQ33702827-04D9F379-FFE7-4089-86D0-99B247F5A701Q33757057-7AF430DE-9F74-442C-A818-203F0081529DQ33917455-8B6B7B4F-6F36-42B0-A3D0-A5914D10CDA0Q33932379-94E5AF89-5FA8-44F9-B1C8-0736050149EEQ34048134-2F92DDB0-AFA5-468D-BF22-C3002D1759B3Q34050170-B2D80F6F-8FDE-4FEB-9DED-13D07C51735EQ34085163-2ED3C3E1-2473-4735-9077-86A785DA55A8Q34206647-455966B7-7C91-4888-9A92-E8CEA0825ED3Q34292779-A0F282BC-64C5-42FA-9AD7-F49BEEC9AF4AQ34293229-2B689842-AF5F-4E60-BC67-D910BE3A8653Q34340071-C1052DEF-ABAD-4A20-9ABB-BCDA18DB0961Q34390516-D422357F-4F27-4255-A876-286DD74D9121Q34633934-5042EA06-98FF-4DE9-A3B3-6A1D3D9BF701Q34756445-D1CE3690-80E8-44ED-B06C-00ED0C95B43BQ35225035-17E8238A-CE14-4420-9FD8-D762DF549AC0Q35230269-FD285B64-6CFB-4B46-8A75-FE5107C74788Q35745193-B652569D-DABB-45C0-BD30-16FC77C7825CQ35813033-E5B4A41B-7D08-4542-AD2F-0F8CF3CF08CFQ35846896-568FA831-FB42-405B-AE2C-44600A9D62C3Q35904441-5875D2D0-E3F6-49E5-A2DC-E0A387DC825EQ36151341-22417F48-054A-492B-8472-DE98A7AAA456Q36338015-B6336607-D3DB-4B34-A9A6-73853CDCAB85Q36393082-8A0BE2C9-6C0E-4497-812B-86DF1793F027Q36536487-AB8FD86B-678E-4FA4-9F7D-4E5E6AB0D597Q36609527-C6CEEA4E-ABFB-4ADC-A586-21D5FF40C6B3Q36614316-78116261-7BAB-45B5-80E2-8B0BA999AAF6Q36719073-35D90255-E619-4B18-B6D4-F215C2B8638FQ36732425-30AC4CAF-B055-41C6-A0BD-582E457DC07BQ36750123-EDC5BB5E-D02B-4C7E-B2A2-81C47FEFA84C
P2860
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Proliferative markers as progn ...... east cancer: where are we now?
@ast
Proliferative markers as progn ...... east cancer: where are we now?
@en
type
label
Proliferative markers as progn ...... east cancer: where are we now?
@ast
Proliferative markers as progn ...... east cancer: where are we now?
@en
prefLabel
Proliferative markers as progn ...... east cancer: where are we now?
@ast
Proliferative markers as progn ...... east cancer: where are we now?
@en
P2093
P2860
P356
P1433
P1476
Proliferative markers as progn ...... east cancer: where are we now?
@en
P2093
C Sotiriou
D Larsimont
E Azambuja
M J Piccart
P2860
P304
P356
10.1093/ANNONC/MDI352
P577
2005-06-24T00:00:00Z